Report Overview
Nicotinamide mononucleotide (NMN) is an intermediate of NAD+ biosynthesis produced from nicotinamide through nicotinamide phosphoribosyltransferase (NAMPT) and also referred to as NMN or nicotinamide ribotide. In recent studies of NMN applications to prevention and diagnosis of agedependent diseases such as diabetes, neurodegenerative disorder, cardiac disease etc., it has become one of hottest biomarkers on discussion for anti-aging, lately.
Market Shares
The global Beta-Nicotinamide Mononucleotide (NMN) market size was estimated at USD 360 million in 2023 and is projected to reach USD 913.45 million by 2032, exhibiting a CAGR of 10.90% during the forecast period.
North America Beta-Nicotinamide Mononucleotide (NMN) market size was estimated at USD 112.15 million in 2023, at a CAGR of 9.34% during the forecast period of 2025 through 2032.
Key Company
• GeneHarbor
• Herbalmax
• Genex Formulas
• Mirailab Bioscience
• Maac10 Formulas
• EffePharm
• Bontac
• CELFULL
• Kingdomway
Market Segmentation
By Type
• Content ?98%
• Content ?98%
By Application
Products
Geographic Segmentation
•North America: USA, Canada, Mexico
•Europe: Germany, UK, France, Russia, Italy, Rest of Europe
•Asia-Pacific: China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific
•South America: Brazil, Argentina, Colombia, Rest of South America
•Middle East and Africa: Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA
